Past, Present and Future of AML
Han Myint, MD
VP, Global Medical Affairs - Myeloid Disease Lead at Celgene Corporation.
Bio: Han has nearly 30 years of experience as an Academic Haematologist and bone marrow transplanter. Han trained in Internal Medicine in Glasgow, Scotland and in Haematology in Glasgow, Bournemouth and Southampton, England. Han is a fellow of Royal College of Physicians and Royal College of Pathologists (London), and maintained his Specialist Registration (Haematology) in the UK. He moved to the US in 2001, where he became the Director of the Haematology & Oncology Fellowship Program at Rush University, where he was instrumental in maintaining the fellowship program and left his legacy of ongoing Haematology Oncology board review classes for many fellows after his departure.
In 2005 he moved on to the University of Colorado Denver as the Director of the Haematological Malignancies Program where he successfully built a FACT accredited and Centre of Excellence-Designated Transplant Program and became a fellow of the American College of Physicians. Through his tenure as Professor of Medicine, he built the program to more than 100 transplants and 5,000 patient visits for hematologic malignancies a year. Han transitioned to industry in 2012 as the Global Head of Medical Affairs for Cell Therapeutics Inc., where he led disease specific strategic planning and execution of all pipeline compounds in Haematological malignancies and all Medical Affairs functions.
Han has a wealth of knowledge and years of experience in Haematological Malignancies and Stem Cell Transplantation, as well as endless energy. Han is a co-chair of the Global Franchise Team (Myeloid Disease) with his commercial counter-part and works very closely with cross-functional teams at Celgene as well as with teams in other regions in creating cohesive Global Disease Strategy for all compounds in the pipeline in Myeloid Disease including AML, MDS, Myelofibrosis, CML, Thalassemia and Sickle Cell Disease.
Date & Time: Wednesday 13 September at 4.00pm followed by drinks and networking
Sponsored by Translational Cancer Research Network